HC Wainwright Reaffirms Buy Rating for Abeona Therapeutics (NASDAQ:ABEO)

HC Wainwright restated their buy rating on shares of Abeona Therapeutics (NASDAQ:ABEO) in a report released on Monday,Benzinga reports. They currently have a $15.00 price objective on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Abeona Therapeutics’ Q4 2024 earnings at ($0.34) EPS, FY2024 earnings at ($1.16) EPS, Q1 2025 earnings at ($0.34) EPS, Q2 2025 earnings at ($0.36) EPS and FY2025 earnings at ($1.17) EPS.

A number of other analysts also recently weighed in on ABEO. Cantor Fitzgerald reissued an “overweight” rating and issued a $18.00 price target on shares of Abeona Therapeutics in a report on Tuesday, October 29th. StockNews.com raised shares of Abeona Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, November 20th.

Abeona Therapeutics Stock Performance

Shares of NASDAQ ABEO opened at $6.41 on Monday. Abeona Therapeutics has a 12 month low of $3.05 and a 12 month high of $9.01. The company has a quick ratio of 6.12, a current ratio of 6.12 and a debt-to-equity ratio of 0.31. The company has a market cap of $278.64 million, a P/E ratio of -2.38 and a beta of 1.52. The business’s 50 day moving average is $6.24 and its two-hundred day moving average is $5.32.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Rosalind Advisors Inc. acquired a new stake in shares of Abeona Therapeutics in the 2nd quarter valued at $7,420,000. Western Standard LLC increased its stake in Abeona Therapeutics by 68.5% in the first quarter. Western Standard LLC now owns 1,361,489 shares of the biopharmaceutical company’s stock valued at $9,871,000 after purchasing an additional 553,377 shares in the last quarter. Renaissance Technologies LLC increased its position in shares of Abeona Therapeutics by 581.6% in the 2nd quarter. Renaissance Technologies LLC now owns 503,293 shares of the biopharmaceutical company’s stock valued at $2,134,000 after buying an additional 429,456 shares in the last quarter. Simplify Asset Management Inc. bought a new stake in Abeona Therapeutics in the 2nd quarter valued at $1,732,000. Finally, abrdn plc raised its position in Abeona Therapeutics by 158.8% in the 3rd quarter. abrdn plc now owns 326,995 shares of the biopharmaceutical company’s stock valued at $2,067,000 after buying an additional 200,647 shares during the last quarter. 80.56% of the stock is owned by institutional investors.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.